Pear VC continued to showcase its portfolio at the intersection of AI and sector-specific innovation this week, emphasizing both healthcare and industrial use cases. The firm highlighted a new Healthcare Playbook podcast episode featuring Valar Labs, an AI oncology diagnostics startup using pathology slides to predict cancer treatment response and extend precision oncology beyond patients with actionable mutations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The Valar Labs feature underscored Pear VC’s exposure to clinically integrated AI tools, noting the company’s GU-focused Vesta pathology portfolio and its translation from academic research to clinical deployment. References to Valar’s previously disclosed $22 million Series A financing co-led by DCVC and Andreessen Horowitz reinforced investor interest in AI-enabled diagnostics and Pear VC’s strategy of backing companies with clear regulatory and commercial pathways.
Beyond oncology, Pear VC spotlighted TruTec, a PearX W26 cohort company automating construction project estimation with computer vision applied to aerial imagery. TruTec, launched in January 2026, reportedly already serves dozens of customers and targets an estimated $17 billion annual spend on largely manual estimation workflows, aiming to let contractors bid on more projects without increasing headcount.
These updates follow recent Pear VC activity across healthcare, industrial automation, and insurtech, including Paxos Health’s AI platform for insurance appeals and Greatly Health’s integrated cancer care model with clinically validated outcomes. The firm also continues to back automation-focused startups such as Even Platforms, which builds modular robotic machine shops, and Quinn, an AI-native commercial property insurance brokerage.
Collectively, the week’s communications reinforce Pear VC’s strategy of sector-diversified investing anchored in AI, automation, and workflow optimization. If portfolio companies like Valar Labs and TruTec achieve broader adoption, Pear VC stands to benefit from exposure to high-growth verticals, while continuing to navigate the execution, regulatory, and competitive risks inherent in early-stage venture investing.